Research on Determining Normal Binding Extent of Dopamine Transporter Binding Ratio using 123I-FP-CIT SPECT

Research on Determining Normal Binding Extent of Dopamine Transporter Binding Ratio using 123I-FP-CIT SPECT - Normal Binding Extent of Dopamine Transporter Scintigraphy using 123I-FP-CIT SPECT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018045

Enrollment

Registered

2015-06-30

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal healthy control

Interventions

To perform dopamine transporter scintigraphy using 123I -FP-CIT intravenous injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Japanese male/female volunteers who are healthy 2) Ages between 50- 90 (as of the consent acquisition date) 3) Individuals judged to be able to undergo necessary examinations on the designated dates after receiving their consent 4) Individuals with the total score of UPDRS part III held within 3 months before and after the consent acquisition date being 0 for the subjects 60 years or younger,or less than 5 for the subjects 61 years or older 5) Individuals whose cranial MRI taken within 3 months before and after the consent acquisition date was normal. Brain atrophy appropriate for age or small lacunar infarction is acceptable. 6) Individuals who can submit a written letter of consent to join this study

Exclusion criteria

Exclusion criteria: 1) Individuals who are pregnant, possibly pregnant, or lactating 2) Individuals with past history of alcoholism, or alcoholics currently under treatment 3) Individuals with past history of epilepsy, or epileptics currently under treatment 4) Individuals with less than 6-year education 5) Individuals who are prescribed with antidepressant or psychotropics, or sedatives including anti-anxiety agents for a long time 6) Individuals with past history of mental or neurological illnesses which affect cognitive functions 7) Individuals with serious complications such as hepatopathy, nephropathy, or endocrinopathy 8) Individuals taking the below mentioned drugs that are considered to affect on accumulation of 123I FP-CIT in the brain within a month after administering the same: cocaine hydrochloride, mazindol, methylphenidate hydrochloride, sertraline hydrochloride, and selective serotonin reuptake inhibitor 9) Individuals judged inappropriate for accomplishing our objective by the principal investigator, researchers in charge, or cooperative researchers

Design outcomes

Primary

Measure	Time frame
To establish normal extent (50-79 years of age) on specific binding ratio (SBR) and asymmetry index (AI)	—

Countries

Japan

Contacts

Public ContactYumiko Motoi

Graduate School of Medicine, Juntendo University Department of Neurology

motoi@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026